Ivabradine

DEA Class; Rx

Common Brand Names; Corlanor

• I(f) Current Inhibitors

Indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with LVEF ≤35%, who are in sinus rhythm with resting heart rate ≥70 bpm and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use

Acute decompensated heart failure

Clinically significant hypotension

Sick sinus syndrome, sinoatrial block, or third-degree AV block (unless a functioning demand pacemaker is present)

Clinically significant bradycardia

Severe hepatic impairment

Pacemaker dependence (heart rate maintained exclusively by the pacemaker)

Concomitant use of strong CYP3A4 inhibitors

Bradycardia (10%)

Hypertension or increased blood pressure (8.9%)

Atrial fibrillation (8.3%)

Luminous phenomena (phosphenes) or visual brightness (2.8%)

Syncope, hypotension

Angioedema, erythema, rash, pruritus, urticaria

Vertigo, diplopia, visual impairment

Torsade de pointes, ventricular fibrillation, ventricular tachycardia

There are no adequate and well-controlled studies in pregnant women to inform any drug-associated risks

Advise females of childbearing potential to use effective contraception

Unknown if distributed in human breast milk